0K4.F - Akero Therapeutics, Inc.
Akero Therapeutics, Inc.
601 Gateway Boulevard
Suite 350
South San Francisco, CA 94080
United States
650 487 6488
https://www.akerotx.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 41
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Andrew Cheng M.D., Ph.D. | Pres, CEO & Director | 1.22M | 4.86M | 1967 |
| Dr. Jonathan M. Young J.D., Ph.D. | Co-Founder, Exec. VP, COO & Sec. | 763.3k | 1.56M | 1970 |
| Dr. Timothy Rolph | Co-Founder & Chief Scientific Officer | 819.4k | 1.3M | 1954 |
| Mr. William R. White J.D. | Exec. VP, CFO, Treasurer & Head of Corp. Devel. | 768.4k | 2.31M | 1973 |
| Ms. Catriona Yale | Exec. VP & Chief Devel. Officer | 754.8k | N/A | 1972 |
| Mr. Patrick Lamy | Sr. VP of Commercial Strategy | N/A | N/A | 1973 |
| Mr. John J. Schembri | VP of Fin. & Controller | N/A | N/A | 1962 |
Description
Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company is also conducting a Phase 2b clinical trial to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Corporate Governance
Akero Therapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2023 is 8. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 8; Compensation: 8.
